The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours.
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
BeiGene And Nanolek Announce Approval In Russia For BRUKINSA For Treatment Of Patients With Relapsed Or Refractory Mantle Cell Lymphoma
This marks the first regulatory approval for BRUKINSA in Russia
BRUKINSA is now approved for the treatment of MCL in ten countries, following the U.S., China, Canada, Australia, and others
BeiGene is committed to
SVB Leerink Maintains Outperform on BeiGene, Lowers Price Target to $414
SVB Leerink analyst Andrew Berens maintains BeiGene (NASDAQ:BGNE) with a Outperform and lowers the price target from $417 to $414.
Bernstein Initiates Coverage On BeiGene with Outperform Rating, Announces Price Target of $431
Bernstein initiates coverage on BeiGene (NASDAQ:BGNE) with a Outperform rating and announces Price Target of $431.
BeiGene Late Sunday Reported Its BRUKINSA Approved In Australia For Treatment Of Adults With Mantle Cell Lymphoma Who Have Received At Least 1 Prior Therapy
Marks BRUKINSA’s second approved indication in Australia, on the heels of its recent initial approval in Waldenström’s macroglobulinemia
To date, BRUKINSA is approved in mantle cell lymphoma in nine
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
Notable Beigene Insider Trades $3.11 Million In Company Stock
Jane Huang, Cmo And Hematology at Beigene (NASDAQ:BGNE), made a large buy and sell of company shares on September 20, according to a new SEC filing.